Adagene
Redefining the design and discovery of therapeutic antibodies
Redefining the design and discovery of therapeutic antibodies
Adagene Inc. (Nasdaq: ADAG) is a biotechnology company founded in 2012, committed to redefining the design and discovery of therapeutic antibodies. The company's slogan, "Redefining the design and discovery of therapeutic antibodies," reflects its core mission. Adagene leverages computational biology and artificial intelligence to design novel antibodies addressing unmet patient needs. Its proprietary DPL platform, consisting of NEObody, SAFEbody™, and POWERbody™ technologies, powers its highly differentiated pipeline featuring novel immunotherapy programs. Adagene has attracted a Post-IPO Equity investment on 11 February 2021, highlighting investor confidence in its innovative approach. The company has also established strategic collaborations with reputable global partners, positioning itself at the vanguard of science in the Biotechnology and Health and Wellness industries.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Post-IPO Equity | Unknown | - | 11 Feb 2021 | |
| Series D | $69.00M | 5 |
|
09 Jan 2020 |
| Series C | $50.00M | 5 |
|
27 Mar 2018 |
| Series B | $28.00M | 5 |
|
29 Jan 2016 |
| Series A | $8.00M | 2 |
|
08 Dec 2014 |
No recent news or press coverage available for Adagene.
We care about your data, and we'd love to use cookies make your experience better.
